Floatz logo

Trastuzumab

Urethra Cancer

National Cancer Institute (NCI)monoclonal_antibodyPhase 2Dormant
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
95/ 100

Competitive context

16 Active assets in the Urethra Cancer cohort.

Asset / SponsorPhaseRating
Vinflunine
Dr Anders Ullén
Phase 2BB
Carboplatin
Jonsson Comprehensive Cancer Center
Phase 2BB
Cis-Diamminedichloroplatinum Ii
Jonsson Comprehensive Cancer Center
Phase 1/2B
Enfortumab Vedotin (Fully Human Monoclonal Antibody Conjugated To A Cytotoxic Agent Monomethyl Auristatin E (Mmae) Targeting Nectin-4)
Emory University
Phase 2B
Cabozantinib
National Cancer Institute (NCI)
Phase 2B

View all 29 →

Same molecule, other indications

Trastuzumab is also rated in:

breast carcinomaActive
BBB
Indicative · Phase 4
76 / 100
View asset →
inflammatory breast carcinomaActive
BBB
Indicative · Phase 3
74 / 100
View asset →
HER2 positive breast carcinomaActive
BB
Indicative · Phase 4
71 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →